Transcatheter Embolization and Occlusion Devices Market Set for Strong Growth Through 2035
The global transcatheter embolization and occlusion devices market was valued at USD 6.33 billion in 2025 and is projected to reach USD 12.14 billion by 2035, expanding at a CAGR of 7.5% during the forecast period.
Growth in this market is being fueled by the increasing demand for minimally invasive procedures, the rising burden of cancer and vascular diseases, and the growing use of embolization technologies in emergency and chronic care settings.
The transcatheter embolization and occlusion devices market size was evaluated at USD 5.89 Bn in 2025 and is expected to be worth around USD
Why the Market is Expanding
Rising use of interventional radiology in oncology and vascular care
Increasing preference for safer, less invasive treatment options
Growing adoption of liquid embolic agents, vascular plugs, and drug-eluting beads
Expansion of advanced treatment capabilities in hospitals and ambulatory surgical centers
Key Market Highlights
Non-coil devices are seeing strong traction due to innovation and broader use in complex procedures
Liquid embolic agents are emerging as one of the fastest-growing segments, especially in neurovascular and tumor-related applications
Oncology continues to dominate application demand, supported by the increasing use of TACE and tumor embolization
Hospitals remain the leading end-users, while ambulatory surgical centers are gaining momentum due to cost-effective outpatient care
Leading Companies
Major players shaping the market include:
BTG plc
Boston Scientific Corporation
Medtronic plc
Penumbra, Inc.
Cook Medical